345 related articles for article (PubMed ID: 19912636)
1. Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain.
Ma L; Uchida H; Nagai J; Inoue M; Chun J; Aoki J; Ueda H
Mol Pain; 2009 Nov; 5():64. PubMed ID: 19912636
[TBL] [Abstract][Full Text] [Related]
2. Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain.
Ma L; Uchida H; Nagai J; Inoue M; Aoki J; Ueda H
J Pharmacol Exp Ther; 2010 May; 333(2):540-6. PubMed ID: 20123931
[TBL] [Abstract][Full Text] [Related]
3. Autotaxin and lysophosphatidic acid1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine.
Nagai J; Uchida H; Matsushita Y; Yano R; Ueda M; Niwa M; Aoki J; Chun J; Ueda H
Mol Pain; 2010 Nov; 6():78. PubMed ID: 21062487
[TBL] [Abstract][Full Text] [Related]
4. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid.
Inoue M; Xie W; Matsushita Y; Chun J; Aoki J; Ueda H
Neuroscience; 2008 Mar; 152(2):296-8. PubMed ID: 18280050
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATX-mediated conversion to LPA, an initiator of neuropathic pain.
Inoue M; Ma L; Aoki J; Ueda H
J Neurochem; 2008 Dec; 107(6):1556-65. PubMed ID: 19014389
[TBL] [Abstract][Full Text] [Related]
6. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain.
Inoue M; Ma L; Aoki J; Chun J; Ueda H
Mol Pain; 2008 Feb; 4():6. PubMed ID: 18261210
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidic acid and its receptors LPA1 and LPA3 mediate paclitaxel-induced neuropathic pain in mice.
Uchida H; Nagai J; Ueda H
Mol Pain; 2014 Nov; 10():71. PubMed ID: 25411045
[TBL] [Abstract][Full Text] [Related]
8. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid.
Kishi Y; Okudaira S; Tanaka M; Hama K; Shida D; Kitayama J; Yamori T; Aoki J; Fujimaki T; Arai H
J Biol Chem; 2006 Jun; 281(25):17492-17500. PubMed ID: 16627485
[TBL] [Abstract][Full Text] [Related]
9. Loss of spinal substance P pain transmission under the condition of LPA1 receptor-mediated neuropathic pain.
Inoue M; Yamaguchi A; Kawakami M; Chun J; Ueda H
Mol Pain; 2006 Aug; 2():25. PubMed ID: 16914035
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia.
Zeng Y; Kakehi Y; Nouh MA; Tsunemori H; Sugimoto M; Wu XX
Prostate; 2009 Feb; 69(3):283-92. PubMed ID: 19025891
[TBL] [Abstract][Full Text] [Related]
11. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression.
Panupinthu N; Lee HY; Mills GB
Br J Cancer; 2010 Mar; 102(6):941-6. PubMed ID: 20234370
[TBL] [Abstract][Full Text] [Related]
12. Involvement of lysophosphatidic acid-induced astrocyte activation underlying the maintenance of partial sciatic nerve injury-induced neuropathic pain.
Ueda H; Neyama H; Nagai J; Matsushita Y; Tsukahara T; Tsukahara R
Pain; 2018 Nov; 159(11):2170-2178. PubMed ID: 29939962
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosis.
Uranbileg B; Ito N; Kurano M; Kano K; Uchida K; Sumitani M; Aoki J; Yatomi Y
Sci Rep; 2021 Feb; 11(1):3984. PubMed ID: 33597645
[TBL] [Abstract][Full Text] [Related]
14. Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.
Zhang R; Wang J; Ma S; Huang Z; Zhang G
BMC Cell Biol; 2011 Mar; 12():11. PubMed ID: 21406114
[TBL] [Abstract][Full Text] [Related]
15. An LPA species (18:1 LPA) plays key roles in the self-amplification of spinal LPA production in the peripheral neuropathic pain model.
Ma L; Nagai J; Chun J; Ueda H
Mol Pain; 2013 Jun; 9():29. PubMed ID: 23773289
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic Acid Receptor 1- and 3-Mediated Hyperalgesia and Hypoalgesia in Diabetic Neuropathic Pain Models in Mice.
Ueda H; Neyama H; Matsushita Y
Cells; 2020 Aug; 9(8):. PubMed ID: 32824296
[TBL] [Abstract][Full Text] [Related]
17. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1.
Hama K; Aoki J; Fukaya M; Kishi Y; Sakai T; Suzuki R; Ohta H; Yamori T; Watanabe M; Chun J; Arai H
J Biol Chem; 2004 Apr; 279(17):17634-9. PubMed ID: 14744855
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic acid as the initiator of neuropathic pain.
Ueda H
Biol Pharm Bull; 2011; 34(8):1154-8. PubMed ID: 21804198
[TBL] [Abstract][Full Text] [Related]
19. Autotaxin and lysophosphatidic acid stimulate intestinal cell motility by redistribution of the actin modifying protein villin to the developing lamellipodia.
Khurana S; Tomar A; George SP; Wang Y; Siddiqui MR; Guo H; Tigyi G; Mathew S
Exp Cell Res; 2008 Feb; 314(3):530-42. PubMed ID: 18054784
[TBL] [Abstract][Full Text] [Related]
20. Alteration of the lysophosphatidic acid and its precursor lysophosphatidylcholine levels in spinal cord stenosis: A study using a rat cauda equina compression model.
Uranbileg B; Ito N; Kurano M; Saigusa D; Saito R; Uruno A; Kano K; Ikeda H; Yamada Y; Sumitani M; Sekiguchi M; Aoki J; Yatomi Y
Sci Rep; 2019 Nov; 9(1):16578. PubMed ID: 31719574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
